Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ136113640,29
KB119912000,00
PKN94,6694,682,27
Msft476,91477,5-0,16
Nokia5,6245,631,08
IBM301,52302,96-0,11
Mercedes-Benz Group AG61,161,131,93
PFE25,3925,410,43
09.01.2026 11:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 08.01.2026
ICU Medical Inc (ICUI.O, NASDAQ Cons)
Závěr k 8.1.2026 Změna (%) Změna (USD) Objem obchodů (USD)
151,65 0,88 1,33 248 383
Premarket09.01.2026 10:05:57
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (USD)
- 62,18 - - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 09.01.2026
Popis společnosti

Business Summary: ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, ICU Medical Inc revenues decreased 4% to $1.69B. Net income totaled $16.5M vs. loss of $93.9M. Revenues reflect Vital Care segment decrease of 46% to $358.2M, Consumables segment decrease of 48% to $266.2M, United States segment decrease of 8% to $1.03B. Net Income reflects Selling, general and administrative decrease of 2% to $468M (expense).



  • Poslední aktualizace: 09.01.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Co-Founder, Executive DirectorGurdial Sanghera-
Chief Executive Officer, Executive DirectorFrancis Van Parys-02.03.202602.03.2026
Chief Financial Officer, Executive DirectorNick Keher-22.01.202422.01.2024
Chief Operating OfficerTimothy Cowper-10.06.202401.01.2019
Senior Vice President, General CounselJordan Herman-
Senior Vice President - Sales and Commercial OperationsRich Compton-01.01.2022
Senior Vice President - Global Human ResourcesSarah Lapworth-
Senior Vice President - Strategic Communications and Corporate AffairsZoe Mcdougall-
Senior Vice President - Corporate and Business DevelopmentJohn Schoellerman-
Chief Product and Marketing OfficerRosemary Dokos-11.11.2024